Key Points
- Insider selling: EVP/director Thomas Tray sold a total of 3,374 Incyte shares across Dec. 18–19 (600 shares at $98.25 and 2,774 shares at $100), reducing his holdings to 22,973 shares (a 2.55% decrease).
- Incyte posted a strong quarter on Oct. 28, beating estimates with $2.26 EPS (vs. $1.65 expected) and $1.37 billion in revenue, up about 20% year‑over‑year; analysts forecast roughly 4.86 EPS for the fiscal year.
- Analyst views are mixed—several firms raised price targets (e.g., Guggenheim $125, Barclays $115), but the consensus rating is a Hold with a $99.07 target while the stock trades near $100.
Incyte Corporation (NASDAQ:INCY - Get Free Report) insider Thomas Tray sold 600 shares of the firm's stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $98.25, for a total value of $58,950.00. Following the transaction, the insider directly owned 22,973 shares in the company, valued at approximately $2,257,097.25. This represents a 2.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Thomas Tray also recently made the following trade(s):
- On Friday, December 19th, Thomas Tray sold 2,774 shares of Incyte stock. The shares were sold at an average price of $100.00, for a total transaction of $277,400.00.
Incyte Trading Down 1.9%
INCY stock opened at $100.71 on Tuesday. The company has a market capitalization of $19.77 billion, a PE ratio of 16.87, a price-to-earnings-growth ratio of 0.70 and a beta of 0.81. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.13 and a current ratio of 3.20. Incyte Corporation has a one year low of $53.56 and a one year high of $109.28. The company's 50 day moving average price is $98.53 and its two-hundred day moving average price is $85.09.
Incyte (NASDAQ:INCY - Get Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $2.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.65 by $0.61. The company had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.26 billion. Incyte had a net margin of 24.69% and a return on equity of 26.56%. The firm's revenue was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.07 EPS. As a group, analysts predict that Incyte Corporation will post 4.86 earnings per share for the current fiscal year.
Institutional Trading of Incyte
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Banque Transatlantique SA bought a new position in Incyte during the 1st quarter valued at approximately $26,000. Harbor Capital Advisors Inc. purchased a new stake in Incyte during the 3rd quarter valued at $26,000. FNY Investment Advisers LLC bought a new position in Incyte in the second quarter valued at about $27,000. Root Financial Partners LLC bought a new position in shares of Incyte in the 3rd quarter worth approximately $28,000. Finally, Quent Capital LLC bought a new position in Incyte in the third quarter worth approximately $30,000. 96.97% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on INCY shares. Guggenheim upgraded Incyte from a "neutral" rating to a "buy" rating and set a $125.00 target price for the company in a report on Monday, November 3rd. Barclays increased their price objective on Incyte from $101.00 to $115.00 and gave the company an "overweight" rating in a research note on Monday, November 24th. Royal Bank Of Canada lifted their target price on shares of Incyte from $81.00 to $84.00 and gave the stock a "sector perform" rating in a research note on Wednesday, October 29th. JPMorgan Chase & Co. upped their price target on shares of Incyte from $73.00 to $89.00 and gave the company a "neutral" rating in a report on Thursday, October 9th. Finally, Wall Street Zen raised shares of Incyte from a "buy" rating to a "strong-buy" rating in a report on Saturday, November 1st. Eight investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $99.07.
View Our Latest Stock Analysis on INCY
Incyte News Summary
Here are the key news stories impacting Incyte this week:
- Positive Sentiment: Japan regulatory wins expand commercial footprint — Japan approved Zynyz (retifanlimab) for first‑line advanced anal cancer and approved Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma. These approvals support additional revenue and market expansion in a major market. Article Title Article Title
- Neutral Sentiment: Momentum/analyst note: a Zacks piece flagged a recent ~5.5% rally and above‑average volume but warned that recent estimate revisions may limit near‑term upside — supportive of interest but not a clear buy signal on its own. Article Title
- Negative Sentiment: Insider selling: EVP and other insiders reported large sales — Incyte EVP sold about $5.25M of stock, and director/officer Thomas Tray disclosed sales totaling 3,374 shares across Dec. 18–19 (~$98–$100 per share). Large, concentrated insider sales can signal near‑term selling pressure or raise governance questions. Article Title SEC Filing
About Incyte
(
Get Free Report)
Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company's research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.
The company's flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
